Oxybutynin hydrochloride for treating neurogenic detrusor overactivity

Oxybutynin hydrochloride is in clinical development for the treatment of neurogenic detrusor overactivity (NDO), in patients managing bladder emptying by clean intermittent catheterisation. Damage to the spinal cord, via spina bifida, multiple sclerosis or injuries, can disrupt communication between the spinal cord and bladder causing NDO. NDO increases pressure in the bladder and decreases the volume of urine the bladder can hold, leading to unexpected and frequent urine leakage (urinary incontinence), increased urinary tract infection (UTIs) and vesicoureteral reflux. Treatment with oral anticholinergics are not effective in all NDO patients and are associated with substantial side effects.